Individual needs vary, so treatment plans are tailored based on health history and desired outcomes
Rossignol P, Masson S, Barlera S et al (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val- HeFT trials
Expected timeline: NDA filing Q4 2026, FDA review in 2027, possible approval late 2027, market launch 2028
Ozempic (semaglutide) is a type of medication used to manage blood sugar levels in Type 2 diabetes patients
At their renewal, they have the ability to revert to current Standards option if they sign additional documentation
While MEDVi doesnt share precise success rates, clinical trials of GLP-1based medications such as semaglutide and tirzepatide have shown average weight loss of roughly 10%15% (or more) of starting body weight over about 11.5 years, when combined with lifestyle changes